Case Report
Copyright ©The Author(s) 2024.
World J Clin Cases. Apr 26, 2024; 12(12): 2092-2098
Published online Apr 26, 2024. doi: 10.12998/wjcc.v12.i12.2092
Table 1 Description and characteristics of assisted reproductive technology cycles

Cycle 1
Cycle 2
Cycle 3
Cycle 4
Cycle 5
COH protocolGnRH-A LongGnRH-AntNatural cycleLuteal phaseNatural cycle
Initiation dose (IU)200225-225-
Total dose of gonadotropin (IU)19752025-2025-
Duration of gonadotropin (d)99-9-
E2 level on the day of HCG injection6605.245822.55189.602239.37172.30
LH level on the day of HCG injection1.540.574.871.864.04
P level on the day of HCG injection2.052.560.287.380.21
No. of follicles (≥ 18 mm)36040
No. of follicles (≥ 14 mm)98181
Ovulation trigger (dose)6000 IU (HCG)2000 IU (HCG) + 0.2 mg
(GnRH agonist)
0.1 mg (GnRH agonist)6000 IU (HCG)0.1 mg (GnRH agonist)
Interval between HCG administration and oocyte retrieval (h)35.5 h35 h35 h35 h34 h
Number of retrieved oocytes12151121
Fertilization modeR-ICSIICSIICSIICSI-
No. of MII8130110
No. of GV2100-
No. of 2PN510-8-
No. of D2 zygote510-8-
No. of D3 embryos57-6-
No. of blastocysts00-0-
No. of transferred embryos1 (FET)----
Pregnancy outcomeNot pregnantNo transferable embryosNo transferable embryosNo transferable embryosNo transferable embryos
Table 2 Results of sequencing mutation sites in the coding region of the TUBB8 gene in the patient (female)
Chromosomal location
Variant naming
Zygotic type
Source of variation
TUBB8Chr 93730NM_177987.3: c.602G>T(p.C201F)Not includedHeterozygousUnknown
Table 3 Results of mutation site verification in the patient's parents
Verification site
Verification results
FatherTUBB8NM_177987.3c.602G>THeterozygous variation